OPKO Health, Inc. (OPK)
|Net Income (ttm)||-202.12M|
|Day's Range||2.30 - 2.46|
|52-Week Range||2.15 - 5.25|
|Price Target||6.63 (+170.6%)|
|Earnings Date||Aug 4, 2022|
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers ... [Read more...]
Financial PerformanceFinancial Statements
According to 9 analysts, the average rating for OPK stock is "Buy." The 12-month stock price forecast is 6.63, which is an increase of 170.61% from the latest price.
OPKO Health (OPK) delivered earnings and revenue surprises of -100% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. fina...
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and a few strategic agreements.
The Dow Jones surged by more than 800 points on Friday. Investors, meanwhile, focused on some notable insider trades.
Bullish insider trading transactions are intriguing for formulating stock picks, particularly during a corrective period in the markets. The post 9 Stock Picks With Important Insider Trading Signals to ...
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
The company topped Q1 revenue estimates and announced a key new acquisition.
OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 6.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infe...
Transaction to be discussed during OPKO's first quarter 2022 conference call today at 4:30 p.m. ET
Volume-weighted average price or VWAP is the ratio of total volume traded divided by the total volume traded for a chosen time frame. VWAP is an important indicator for intraday trading as it graphicall...
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and regulatory approvals.
New research underscores the value of sharing genomic information to advance gene matching for diagnosis and discovery GAITHERSBURG, Md., March 16, 2022 /PRNewswire/ -- GeneDx, Inc., a leader in genomic...
ROSWELL, Ga., March 1, 2022 /PRNewswire/ -- Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic analys...
OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.
A bottom-line earnings miss adds to a general bearishness on coronavirus stocks.
OPKO Health (OPK) delivered earnings and revenue surprises of -266.67% and 19.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today
In the latest trading session, OPKO Health (OPK) closed at $3.15, marking a +0.32% move from the previous day.
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financia...
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
Pfizer and OPKO's Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for T...
NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation lo...
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 penny stocks outperforming Facebook Meta stock today The post 4 Penny Stocks To Buy For Under $5 Outperforming FB Stock In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...